Navigation Links
National Stem Cell Holding, Inc. to Present Keynote Address at The Stem Cell Partnering Series Inaugural Meeting in San Diego
Date:2/26/2008

Tuesday February 26, 2008 9:15 am ET

MOUNTAINSIDE, N.J., Feb. 26 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (Pink Sheets: NHGI) today announced that its President Michael Cohen will present a Keynote Address, "A New Collaboration Model for Government Agencies, Academic Institutions and Development Stage Biotech Companies," at the Inaugural meeting of The Stem Cell Partnering Series: Fostering Business Collaborations & Careers in Stem Cell Science, February 28- 29, 2008, to be held at the University of California San Diego.

National Stem Cell President, Michael Cohen, stated, "I am pleased to participate in this event which has focused much needed attention to two critically important issues facing the stem cell / Regenerative Medicine industry: the need for increasing and improving strategic collaborations among the key stakeholders namely, development stage biotech companies, academic Institutions and government agencies, together with the attendant need to develop and recruit trained scientific personnel to meet both current and future industrial demands. Failure to address these issues rapidly and effectively within the U.S. risks the significant loss of intellectual property research and development and value to industrial sectors abroad."

The Stem Cell Partnering Series is a not-for-profit organization that actively supports the development and sustainability of the stem cell industry by fostering business collaborations and career development.

For more information on National Stem Cell Holding, Inc. please contact us at the company website: http://www.nationalstemcell.com or http://www.pinksheets.com.

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a hybrid biotechnology company focused on developing therapeutics based upon the use of human stem cells and their derivatives. The term 'hybrid' refers to both the business model as well its product line. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, neurodegenerative diseases and auto immune conditions. In addition to its work with stem cell therapeutics, the Company is leveraging its commercial infrastructure and product development capabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissue Bank and IVF laboratory) and National Stem Cell Blood Laboratories Inc (cord blood banking program), and its affiliate, Decouverte Cosmetique, Inc. (cosmetics). The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company's multi-facetted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions.

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:

Michael Cohen

Phone: (212)792-6188

ir@nationalstemcell.com


'/>"/>
SOURCE National Stem Cell Holding, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy
2. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
4. IBF Conferences Inc., (International Business Forum) and BioEnterprise Present the 2nd Annual Global Healthcare Investing Conference
5. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
6. National Fire Protection Association (NFPA) Sets New National Standard for CO Screening by Pulse CO-Oximetry(TM)
7. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
8. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
9. Siemens and National Jewish Medical and Research Center Form Strategic Alliance to Advance Shared Vision of Personalized Medicine
10. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SAN DIEGO , Feb. 12, 2016 Biocom, ... life science community, took a group of San ... as part of its 2016 Precision Medicine Advocacy Fly-In. ... at the Food and Drug Administration (FDA), the Centers for ... (NIH), as well as San Diego U.S. Representatives Susan ...
(Date:2/12/2016)... MedGenome,s Commitment Will Help ... of Complex Diseases Such as Cancer, Metabolic Disorders, ... --> --> MedGenome, the market ... leading provider of genomics research services globally, today ... GenomeAsia 100K consortium as a founding member. ...
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... QGEN ; Frankfurt Prime Standard: QIA) today announced the ... Panels for gene expression profiling, expanding QIAGEN,s portfolio of ... panels enable researchers to select from over 20,000 human ... discover interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals and ... premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in ...
Breaking Biology Technology:
(Date:1/20/2016)... MINNETONKA, Minn. , Jan. 20, 2016   ... that supports the entire spectrum of clinical research, is ... in 2015. MedNet,s significant achievements are the result of ... of) iMedNet eClinical , it,s comprehensive, ... --> --> Key MedNet growth ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):